Fedora Pharmaceuticals, Inc. announced it was named “Company of the Year” by BioAlberta during the Association’s 16th Annual General Meeting and Awards Gala. The award recognizes life sciences companies demonstrating significant achievement within Alberta’s marketplace through strong performance or leadership.
Fedora Pharmaceuticals is an excellent example of what can happen when scientific excellence and business acumen meet. Alberta may be known for its energy resources, but there is a breadth of talent in our province that is often overlooked.Christopher G. Micetich, Founder, President & CEO
Micetich noted that within three years, Fedora scientists optimized β-lactamase inhibitor candidates, resulting in a licensing deal with Roche valued at up to $750 million in January 2015 — the largest in Canadian life sciences industry history.
About Fedora Pharmaceuticals
Fedora Pharmaceuticals Inc. is an innovative biotech founded in 2011 and headquartered in Edmonton, Alberta, Canada. The company is dedicated to discovering and developing novel antimicrobial drugs to tackle antibiotic resistance (AMR). Fedora’s most advanced candidate is nacubactam, a Phase 3-ready β-lactamase inhibitor being advanced with partner Meiji Seika; Fedora holds key US rights to nacubactam. For more information, visit fedorapharma.com.
